# 7 on 7: The biggest stories from last week you might’ve missed > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/7-on-7-the-biggest-stories-from-last-week-you-mightve-missed/ > **Published:** 2026-05-24T19:12:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:54:08-04:00 > **Clinical Summary:** DEA reclassified cannabis to Schedule III. What this means for clinical practice, research, and patient prescribing authority. --- ✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearch[Medical Marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/)SchedulingHealthcareRegulationFederal Why This Matters # Clinical RelevanceThe DEA’s reclassification of cannabis from Schedule I to Schedule III significantly reduces regulatory barriers for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), enabling clinicians to conduct rigorous studies on cannabis’s therapeutic efficacy and safety profile rather than relying on limited evidence. This change allows healthcare providers to more confidently discuss cannabis as a potential treatment option with patients while facilitating better documentation and integration into electronic health records systems. Clinicians should now anticipate increased patient inquiries about cannabis for various conditions and prepare to provide evidence-based guidance as research capacity expands under the less restrictive scheduling. Clinical Summary The federal reclassification of cannabis from Schedule I to Schedule III represents a significant shift in the regulatory landscape that directly impacts clinical practice by formally acknowledging medical utility and potentially expanding research opportunities. This reclassification signals federal recognition that cannabis has accepted medical use and lower abuse potential compared to Schedule I substances, which may facilitate more rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and pharmacological characterization of cannabis-derived therapeutics. For clinicians, this change could streamline the process of prescribing cannabis-based medications in states where such practice is permitted, reduce barriers to conducting [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), and improve insurance coverage prospects for patients. The reclassification also positions cannabis alongside other controlled substances with established medical applications, suggesting potential progress toward standardized dosing, quality assurance, and evidence-based guidelines that are currently lacking in many cannabis-using patient populations. Clinicians should monitor forthcoming FDA guidance and research developments to understand how this reclassification will translate into updated clinical recommendations and product regulation. Understanding this policy shift enables clinicians to better inform patients about the changing landscape of [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and set realistic expectations about future standardization and evidence availability. Dr. Caplan’s Take “The Schedule III reclassification is clinically significant because it finally allows us to conduct the rigorous pharmacokinetic and drug-interaction studies we’ve needed for two decades, which means I can move from anecdotal evidence to real data when counseling patients about dosing and safety with their other medications.” Clinical Perspective The federal reclassification of cannabis from Schedule I to Schedule III represents a significant shift in regulatory recognition of potential therapeutic applications, though this administrative change does not automatically translate to clinical evidence or standardized dosing protocols. Healthcare providers should recognize that rescheduling facilitates further research and may eventually increase patient access, but the current evidence base for cannabis remains heterogeneous, with most high-quality trials limited to specific conditions like chemotherapy-related nausea or certain seizure disorders. The reclassification could paradoxically complicate clinical practice by creating patient expectations for use beyond evidence-supported indications while still leaving gaps in understanding optimal dosing, long-term safety, drug interactions, and population-specific risks such as effects on adolescent neurodevelopment or impaired driving. Clinicians should stay informed about evolving regulations and evidence, maintain appropriate skepticism about off-label applications, and consider cannabis as one option within a comprehensive 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%207%20on%207%3A%20The%20biggest%20stories%20from%20last%20week%20you%20might%27ve%20missed%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56427)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56427)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%207%20on%207%3A%20The%20biggest%20stories%20from%20last%20week%20you%20might%27ve%20missed%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56427)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://katv.com/news/local/7-on-7-the-biggest-stories-from-last-week-you-mightve-missed-doj-medical-marijuana-schedule-3-majestic-park-softball-jacksonville-shootin-amir-houston-fatal-shooting-arkansas-naacp-fentanyl-overdose-officer-healthcare-ceo-rural-hospitals-lawmakers](https://katv.com/news/local/7-on-7-the-biggest-stories-from-last-week-you-mightve-missed-doj-medical-marijuana-schedule-3-majestic-park-softball-jacksonville-shootin-amir-houston-fatal-shooting-arkansas-naacp-fentanyl-overdose-officer-healthcare-ceo-rural-hospitals-lawmakers) Further Reading Cannabis Policy WireCED Regulatory Digest, Since Last Digest, 1 items CED Clinic Blog[The First Cannabis Drug to Earn FDA Breakthrough Therapy Status for Pain`](https://cedclinic.com/fda-breakthrough-therapy-ver-01-cannabis-chronic-back-pain/) Research Digest[Research Digest: 20 Recent Studies – May 02, 2026](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).